Key Highlights

  • The Phase 3 REGAL trial for galinpepimut-S in AML has reached 78 of the 80 required survival events, putting the company just two events away from triggering the final analysis and topline data disclosure.
  • Slower-than-expected event accumulation has been characterised as a positive clinical signal, suggesting patients are living longer than projected, with the trial targeting median overall survival extension to 12.6 months from 8 months under standard treatment.
  • SLS is trading at $8.32 pre-market June 22, up 3.35% from the June 18 close of $8.05, extending a bounce despite dilution from a shareholder-approved 20 million share increase to the equity incentive plan.

Two Events Away From a Pivotal Readout

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is trading at $8.32 pre-market June 22, up 3.35% from the June 18 close of $8.05. SELLAS is a late-stage clinical biopharmaceutical company developing novel cancer immunotherapies, with lead candidate galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms Tumor 1 protein present across more than 20 tumor types, licensed from Memorial Sloan Kettering Cancer Center.

The primary driver of pre-market interest is the Phase 3 REGAL trial's proximity to its final analysis trigger. The study requires 80 survival events before the final analysis and topline data disclosure, and has now reached 78, meaning just two more events will initiate the readout. The slower-than-expected pace of event accumulation has been consistently highlighted as a positive signal, reflecting patients living longer than originally projected in the trial design, which would be directionally consistent with a treatment benefit from GPS. The trial is considered successful if GPS extends median overall survival to 12.6 months versus 8 months under standard AML maintenance treatment.

The pre-market advance comes despite dilution-related concerns following shareholder approval at the June 16 annual meeting of a 20 million share increase to the equity incentive plan, and the disclosure of a 1.065 million RSU grant to the CEO. The stock is extending a bounce from those dilution headwinds, with investor focus squarely on the imminent REGAL readout as the dominant catalyst.

Beyond REGAL, SELLAS is advancing SLS009, a Phase 2 CDK9 inhibitor for AML developed in partnership with IMPACT-AML, with topline data expected later in 2026, adding pipeline optionality beyond the near-term readout. The company reported $107.1 million in cash at Q1 end, with an additional $28.7 million raised through warrant exercises in April and May, providing runway through the pivotal catalyst.

Valuation and Risk Considerations

SLS reports a negative EPS of $0.23 without a conventional P/E ratio. The 52-week range of $1.39 to $9.51 reflects the dramatic re-rating as the REGAL trial approached its primary endpoint. Key risks include the binary nature of the final readout, the dilutive equity plan expansion, and the uncertainty inherent in overall survival endpoints in oncology trials.

Conclusion

SELLAS is two events away from one of the most anticipated binary catalysts in its history, and the pre-market advance reflects investors maintaining conviction ahead of a readout that will determine whether GPS can redefine AML maintenance standard of care.

FAQs

Q: Why is SLS up 3.35% pre-market June 22?
A: The Phase 3 REGAL trial for galinpepimut-S in AML has reached 78 of 80 required events, putting the company two events away from triggering the final analysis and topline data disclosure.

Q: What does galinpepimut-S target?
A: GPS is a peptide immunotherapy targeting the Wilms Tumor 1 protein present across more than 20 tumor types, currently being evaluated in Phase 3 for AML maintenance and in combination with pembrolizumab across hematologic and solid tumors.

Q: Is the slower event accumulation a positive sign?
A: SELLAS has characterised it as positive, suggesting patients are living longer than projected, which is directionally consistent with a treatment benefit from GPS in the overall survival endpoint.